CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Esperion Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Esperion Therapeutics Inc
3891 Ranchero Drive
Suite 150, Suite 300
Phone: 302-6587581p:302-6587581 ANN ARBOR, MI  48108  United States Ticker: ESPRESPR
Business Summary
Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and delivering cardiometabolic and rare/orphan disease therapies. It markets two oral, once-daily, non-statin therapies for patients struggling to maintain their low-density lipoprotein cholesterol (LDL-C) levels who are at risk of cardiovascular disease and nasal spray, loop diuretic for the treatment of edema associated with congestive heart failure, and hepatic and renal disease. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. NEXLETOL is a first-in-class ACLY inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating LDL receptors. NEXLIZET contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and cholesterol absorption in the intestine. Its Enbumyst is the FDA-approved nasal spray loop diuretic.
(Source: 6-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202612/31/2025YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board J. MartinCarroll 76 6/1/2022 6/1/2022
President, Chief Executive Officer, Director Sheldon L.Koenig 60 5/18/2021 12/15/2020
Chief Financial Officer BenjaminHalladay 40 11/16/2022 11/16/2022
6 additional Officers and Directors records available in full report.

General Information
Number of Employees: 294 (As of 12/31/2025)
Outstanding Shares: 257,431,942 (As of 4/30/2026)
Shareholders: 5
Stock Exchange: NASD
Federal Tax Id: 273015978
Fax Number: 302-6555049
Email Address: info@esperion.com


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, May 29, 2026